Ubs Group Ag Relay Therapeutics, Inc. Transaction History

Ubs Group Ag

$611 Billion
Q3 2025

A detailed history of Ubs Group Ag transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 152,253 shares of RLAY stock, worth $1.01 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

152,253

Previous 173,090 12.04%

Holding current value

$1.01 Million

Previous $598,000 32.78%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$3.22 - $5.22 $67,095 - $108,769	-20,837 Reduced 12.04%	152,253 $794,000
Q2 2025 Aug 14, 2025	SELL	$2.0 - $3.49 $204,936 - $357,613	-102,468 Reduced 37.19%	173,090 $598,000
Q1 2025 May 13, 2025	SELL	$2.62 - $4.92 $177,342 - $333,024	-67,688 Reduced 19.72%	275,558 $721,000
Q4 2024 Feb 14, 2025	BUY	$4.12 - $6.8 $624,270 - $1.03 Million	151,522 Added 79.03%	343,246 $1.41 Million
Q3 2024 Nov 14, 2024	BUY	$6.23 - $9.51 $14,976 - $22,862	2,404 Added 1.27%	191,724 $1.36 Million

Q2 2024 Aug 13, 2024	SELL	$5.9 - $8.02 $581,775 - $790,820	-98,606 Reduced 34.25%	189,320 $1.23 Million
Q1 2024 May 13, 2024	BUY	$7.5 - $12.07 $762,202 - $1.23 Million	101,627 Added 54.55%	287,926 $2.39 Million
Q4 2023 Feb 09, 2024	BUY	$6.01 - $11.48 $753,293 - $1.44 Million	125,340 Added 205.61%	186,299 $2.05 Million
Q3 2023 Nov 09, 2023	SELL	$8.24 - $12.97 $1.1 Million - $1.73 Million	-133,738 Reduced 68.69%	60,959 $512,000
Q2 2023 Aug 11, 2023	BUY	$9.99 - $18.27 $240,099 - $439,101	24,034 Added 14.08%	194,697 $2.45 Million
Q1 2023 May 12, 2023	SELL	$15.0 - $22.76 $1.39 Million - $2.1 Million	-92,437 Reduced 35.13%	170,663 $2.81 Million
Q4 2022 Feb 08, 2023	BUY	$14.16 - $24.02 $3.44 Million - $5.83 Million	242,674 Added 1188.06%	263,100 $3.93 Million
Q3 2022 Nov 10, 2022	SELL	$18.07 - $31.37 $798,820 - $1.39 Million	-44,207 Reduced 68.4%	20,426 $456,000
Q2 2022 Aug 10, 2022	SELL	$13.31 - $34.88 $690,629 - $1.81 Million	-51,888 Reduced 44.53%	64,633 $1.08 Million
Q1 2022 May 16, 2022	BUY	$20.26 - $32.36 $451,453 - $721,077	22,283 Added 23.65%	116,521 $3.49 Million
Q4 2021 Feb 14, 2022	BUY	$26.0 - $37.03 $2.17 Million - $3.09 Million	83,354 Added 765.84%	94,238 $2.89 Million
Q3 2021 Nov 15, 2021	SELL	$29.75 - $37.99 $586,878 - $749,428	-19,727 Reduced 64.44%	10,884 $343,000
Q2 2021 Aug 13, 2021	SELL	$27.5 - $38.19 $347,875 - $483,103	-12,650 Reduced 29.24%	30,611 $1.12 Million
Q1 2021 May 12, 2021	BUY	$32.52 - $61.53 $1.13 Million - $2.14 Million	34,849 Added 414.28%	43,261 $1.5 Million
Q4 2020 Feb 11, 2021	BUY	$35.51 - $54.03 $279,570 - $425,378	7,873 Added 1460.67%	8,412 $350,000
Q3 2020 Nov 12, 2020	BUY	$32.81 - $45.1 $17,684 - $24,308	539 New	539 $23,000

Others Institutions Holding RLAY

# of Institutions

215

Shares Held

168M

Call Options Held

714K

Put Options Held

14.9K

View Full List

About Relay Therapeutics, Inc.

Ticker RLAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 120,219,000
Market Cap $796M
Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...

More about RLAY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account